FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hans Carl Hasselbalch

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Co-author Network

Publications

TOP 3
Sif Gudbrandsdottir; Henrik Birgens; Henrik Frederiksen; Bjarne Anker Jensen; Morten Krogh Jensen; Lars Kjeldsen; Tobias Wirenfeldt Klausen; Herdis Larsen; Hans Torben Mourits-Andersen; Claus Henrik Nielsen; Ove Juul Nielsen; Torben Plesner; Stanislaw Pulczynski; Inge Helleberg Rasmussen; Dorthe Rønnov-Jessen; Hans Carl Hasselbalch
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.
Richard T Silver; Jean-Jacques Kiladjian; Hans Carl Hasselbalch
Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
Hans Carl Hasselbalch
Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hans Carl Hasselbalch (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sif Gudbrandsdottir; Henrik Birgens; Henrik Frederiksen; Bjarne Anker Jensen; Morten Krogh Jensen; Lars Kjeldsen; Tobias Wirenfeldt Klausen; Herdis Larsen; Hans Torben Mourits-Andersen; Claus Henrik Nielsen; Ove Juul Nielsen; Torben Plesner; Stanislaw Pulczynski; Inge Helleberg Rasmussen; Dorthe Rønnov-Jessen; Hans Carl Hasselbalch
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.
Blood 2013;121(11):1976-81.
2013: Richard T Silver; Jean-Jacques Kiladjian; Hans Carl Hasselbalch
Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
Expert review of hematology 2013;6(1):49-58.
2013: Hans Carl Hasselbalch
Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
Leukemia research 2013;37(2):214-20.
2012: Vibe Skov; Mads Thomassen; Ole Weis Bjerrum; Morten K Jensen; Torben A Kruse; Thomas Stauffer Larsen; Caroline Hasselbalch Riley; Hans Carl Hasselbalch
Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance.
Leukemia research 2012;36(11):1387-92.
2012: Vibe Skov; Mads Thomassen; Caroline H Riley; Ole Weis Bjerrum; Hans Carl Hasselbalch; Morten K Jensen; Torben A Kruse; Thomas Stauffer Larsen
Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis.
Experimental hematology 2012;40(9):771-780.e19.
2012: Hans Carl Hasselbalch
Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
Blood 2012;119(14):3219-25.
2012: Christen Lykkegaard Andersen; Olav J Bergmann; Hans Carl Hasselbalch; Thomas Kielsgaard Kristensen; Michael Boe Møller; Marianne Tang Severinsen; Hanne Vestergaard; Ole Weis Bjerrum
Systemic mastocytosis--a systematic review.
Danish medical journal 2012;59(3):A4397.
2012: Ann Madelung; Stefan Scheding; Eva Zetterberg; Ole Weis Bjerrum; Henrik Bondo; Michael Bzorek; Hans Carl Hasselbalch; Elisabeth Ralfkiaer
A novel immunohistochemical sequential multi-labelling and erasing technique enables epitope characterization of bone marrow pericytes in primary myelofibrosis.
Histopathology 2012;60(4):554-60.
2011: Hans Carl Hasselbalch
A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
Expert review of hematology 2011;4(6):637-55.
2011: Waleed Ghanima; Sif Gudbrandsdottir; Hans Carl Hasselbalch; Peter Junker; Attilio Orazi; Leonardo Boiocchi; Xingmin Feng; Julia T Geyer; James B Bussel
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
British journal of haematology 2011;155(2):248-55.
2011: Hans Carl Hasselbalch; Morten K Jensen; Ole Weis Bjerrum; Thomas Stauffer Larsen; Caroline Hasselbalch Riley; Vibe Skov; Mads Thomassen; Torben A Kruse
High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis.
Leukemia research 2011;35(10):1330-4.
2011: Caroline Hasselbalch Riley; Per Thor Straten; Ole Weis Bjerrum; Marie Klinge Brimnes; Hans Carl Hasselbalch; Morten Krogh Jensen; Inge Marie Svane
Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.
Blood 2011;118(8):2170-3.
2011: Malene Risum; Inger Merete Stamp; Henrik Bondo; Michael Bzorek; Michael Holmsgaard Kristensen; Ann Madelung; Hans Carl Hasselbalch
The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2011;119(8):498-504.
2011: Vibe Skov; Mads Thomassen; Ole Weis Bjerrum; Morten K Jensen; Torben A Kruse; Thomas Stauffer Larsen; Caroline Hasselbalch Riley; Hans Carl Hasselbalch
Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis.
European journal of haematology 2011;87(1):54-60.
2011: Daniel El Fassi; Hans Carl Hasselbalch; P Junker; Claus Henrik Nielsen; Laszlo Hegedüs
Systemic adverse events following rituximab therapy in patients with Graves' disease.
Journal of endocrinological investigation 2011;34(7):e163-7.
2011: Hans Carl Hasselbalch; Jean-Jacques Kiladjian; Richard T Silver
Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(18):e564-5.
2011: Hans Carl Hasselbalch; Thomas Stauffer Larsen; Caroline Hasselbalch Riley; Morten Krogh Jensen; Jean-Jacques Kiladjian
Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.
Current drug targets 2011;12(3):392-419.
2011: Tiziano Barbui; Giovanni Barosi; Gunnar Birgegård; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben A Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(6):761-70.
2011: Sif Gudbrandsdottir; Henrik Frederiksen; Henrik Birgens; Claus Henrik Nielsen; Ove Juul Nielsen; Jesper Stentoft; Hans Carl Hasselbalch
[The pathogenesis of primary immune thrombocytopenia].
Ugeskrift for laeger 2011;173(4):274-7.
2011: Sif Gudbrandsdottir; Henrik Frederiksen; Henrik Birgens; Claus Henrik Nielsen; Ove Juul Nielsen; Jesper Stentoft; Hans Carl Hasselbalch
[New treatment options for primary immune thrombocytopenia].
Ugeskrift for laeger 2011;173(4):271-4.
2009: Thomas Stauffer Larsen; Michael Boe Møller; Karin de Stricker; Peter Nørgaard; Jan Samuelsson; Claus Marcher; Morten T Andersen; Ole Weis Bjerrum; Hans Carl Hasselbalch
Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission.
Hematology (Amsterdam, Netherlands) 2009;14(6):331-4.
2009: Christen Lykkegaard Andersen; Hanne Vestergaard; Peter Nørgaard; Peter Felding; Niels Pallisgaard; Inge Hellegaard Rasmussen; Hans Carl Hasselbalch; Ole Weis Bjerrum
[Eosinophilia--pathogenesis, classification and therapy].
Ugeskrift for laeger 2009;171(45):3256-62.
2009: Steen B Laursen; Maja Østergaard Nielsen; Hans Carl Hasselbalch
[The myelodysplastic syndrome and autoimmunity].
Ugeskrift for laeger 2009;171(37):2639-42.
2009: Giovanni Barosi; Gunnar Birgegård; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Jean-Jacques Kiladjian; Eva Lengfelder; Mary Frances McMullin; Francesco Passamonti; John T Reilly; Alessandro M Vannucchi; Tiziano Barbui
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.
Blood 2009;113(20):4829-33.
2009: Thomas Stauffer Larsen; Niels Pallisgaard; Karin de Stricker; Michael Boe Møller; Hans Carl Hasselbalch
Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.
Hematology (Amsterdam, Netherlands) 2009;14(1):11-5.
2009: Hans Carl Hasselbalch
Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
Leukemia research 2009;33(1):11-8.
2008: Jean-Jacques Lataillade; Olivier Pierre-Louis; Hans Carl Hasselbalch; Georges Uzan; Claude Jasmin; Marie-Claire Martyré; Marie-Caroline Le Bousse-Kerdilès
Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence.
Blood 2008;112(8):3026-35.
2008: Thomas Stauffer Larsen; O W Bjerrum; Niels Pallisgaard; M T Andersen; Michael Boe Møller; Hans Carl Hasselbalch
Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.
Annals of hematology 2008;87(10):847-50.
2008: Thomas Kümler; Daniel Hedlund; Robert Hast; Hans Carl Hasselbalch
[Aquagenic pruritus from polycythaemia vera--treatment with paroxetine, a selective serotonin reuptake inhibitor].
Ugeskrift for laeger 2008;170(38):2981.
2008: Philip A Beer; Peter J Campbell; Linda Maree SCOTT; Anthony J Bench; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Hans Carl Hasselbalch; Richard Bowman; Keith Wheatley; Georgina Buck; Claire N Harrison; Anthony R Green
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.
Blood 2008;112(1):141-9.
2008: Hans Carl Hasselbalch; Henrik Birgens; Inge Høgh Dufva; Anne-Marie Dalseg; Peter de Nully Brown; Morten Krogh Jensen; Anette Vangsted
[Novel medical treatment modalities in hematology].
Ugeskrift for laeger 2008;170(24):2115-9.
2008: Thomas Stauffer Larsen; Niels Pallisgaard; Michael Boe Møller; Hans Carl Hasselbalch
High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.
Hematology (Amsterdam, Netherlands) 2008;13(2):71-6.
2008: Thomas Stauffer Larsen; Hans Carl Hasselbalch
[Tyrosine kinase inhibitors in the treatment of polycythemia vera and related conditions. Danish Society of Hematology].
Ugeskrift for laeger 2008;170(12):1031.
2008: Ole Weis Bjerrum; Inge Høgh Dufva; Jesper Stentoft; Hans Carl Hasselbalch
[Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
Ugeskrift for laeger 2008;170(5):331-3.
2008: Thomas Stauffer Larsen; Niels Pallisgaard; Michael Boe Møller; Hans Carl Hasselbalch
Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.
Leukemia 2008;22(1):194-5.
2007: Thomas Stauffer Larsen; Niels Pallisgaard; Michael Boe Møller; Hans Carl Hasselbalch
The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
European journal of haematology 2007;79(6):508-15.
2007: Thomas Stauffer Larsen; Hans Carl Hasselbalch; Niels Pallisgaard; Michael Boe Møller
Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2007;115(11):1267-73.
2007: Claus Henrik Nielsen; Daniel El Fassi; Hans Carl Hasselbalch; Klaus Bendtzen; Laszlo Hegedüs
B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.
Expert opinion on biological therapy 2007;7(7):1061-78.
2007: Eva Zetterberg; Alessandro M Vannucchi; Anna Rita Migliaccio; William Vainchenker; Micheline Tulliez; Renée Dickie; Hans Carl Hasselbalch; Rick Rogers; Jan Palmblad
Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows.
Haematologica 2007;92(5):597-604.
2007: Daniel El Fassi; Claus Henrik Nielsen; Steen J Bonnema; Hans Carl Hasselbalch; Laszlo Hegedüs
B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
The Journal of clinical endocrinology and metabolism 2007;92(5):1769-72.
2007: Thomas Stauffer Larsen; Jacob Haaber Christensen; Hans Carl Hasselbalch; Niels Pallisgaard
The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
British journal of haematology 2007;136(5):745-51.
2007: Hans Carl Hasselbalch; Caroline H Riley
The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders.
Current drug targets 2007;8(2):247-56.
2007: Giovanni Barosi; C Besses; Gunnar Birgegård; Jean Briere; Francisco Cervantes; Guido Finazzi; Heinz Gisslinger; Martin Griesshammer; Luigi Gugliotta; C Harrison; Hans Carl Hasselbalch; Eva Lengfelder; John T Reilly; JJ Michiels; Tiziano Barbui
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.
Leukemia 2007;21(2):277-80.
2007: Thomas Stauffer Larsen; Hans Carl Hasselbalch; Niels Pallisgaard; Gitte B Kerndrup
A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
Cancer genetics and cytogenetics 2007;172(2):107-12.
2006: Hans Carl Hasselbalch; Caroline H Riley
Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?
Leukemia research 2006;30(10):1217-25.
2006: Thomas Stauffer Larsen; Niels Pallisgaard; Jacob Haaber Christensen; Paul Gram-Hansen; Gitte B Kerndrup; Michael Boe Møller; Hans Carl Hasselbalch
[New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Ugeskrift for laeger 2006;168(39):3299-303.
2006: Thomas Stauffer Larsen; Niels Pallisgaard; Jacob Haaber Christensen; Paul Gram-Hansen; Gitte B Kerndrup; Michael Boe Møller; Hans Carl Hasselbalch
[New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].
Ugeskrift for laeger 2006;168(39):3295-9.
2006: Daniel El Fassi; Claus Henrik Nielsen; Hans Carl Hasselbalch; Laszlo Hegedüs
Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion.
Thyroid : official journal of the American Thyroid Association 2006;16(7):709-10.
2006: Jan Samuelsson; Hans Carl Hasselbalch; Oystein Bruserud; Snezana Temerinac; Yvonne Brandberg; Mats Merup; Olle Linder; Magnus Bjorkholm; Heike L Pahl; Gunnar Birgegård
A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.
Cancer 2006;106(11):2397-405.
2006: Daniel El Fassi; Claus Henrik Nielsen; Hans Carl Hasselbalch; Laszlo Hegedüs
The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option.
European journal of endocrinology / European Federation of Endocrine Societies 2006;154(5):623-32.
2006: Peter J Campbell; Martin Griesshammer; Konstanze Döhner; Hartmut Döhner; Rajko Kusec; Hans Carl Hasselbalch; Thomas Stauffer Larsen; Niels Pallisgaard; Stéphane Giraudier; Marie-Caroline Le Bousse-Kerdilès; desterke christophe; Bernadette Guerton; Brigitte Dupriez; Dominique Bordessoule; Pierre Fenaux; Jean-Jacques Kiladjian; Jean-François Viallard; Josette Brière; Claire N Harrison; Anthony R Green; John T Reilly
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.
Blood 2006;107(5):2098-100.
2005: Giovanni Barosi; Dominique Bordessoule; Jean Briere; Francisco Cervantes; Jean-Loup Demory; Brigitte Dupriez; Heinz Gisslinger; Martin Griesshammer; Hans Carl Hasselbalch; Rajko Kusec; Marie-Caroline Le Bousse-Kerdiles; Nicola Liberato; Monia Marchetti; John T Reilly; Juergen Thiele
Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET).
Blood 2005;106(8):2849-53.
2005: Anne Bukh; Francesco Annibale D'Amore; Peter Gimsing; Hans Carl Hasselbalch; Hans E Johnsen; Gitte B Kerndrup; Jørgen S Kristensen; Niels A Peterslund
[Designer drugs and their rational use in clinical hematology].
Ugeskrift for laeger 2005;167(20):2180-3.
2005: Peter Braendstrup; Ole Weiss Bjerrum; Ove Juul Nielsen; Bjarne Anker Jensen; Nielsaage Tøffner Clausen; Per Boye Hansen; Ivan Andersen; Kai Schmidt; Torben M Andersen; Niels A Peterslund; Henrik Birgens; Torben Plesner; Bjarne B Pedersen; Hans Carl Hasselbalch
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
American journal of hematology 2005;78(4):275-80.
2004: Elisabeth Irene Penninga; Bjarne Anker Jensen; Per Boye Hansen; Nielsaage Tøffner Clausen; T Mourits-Andersen; Ove Juul Nielsen; Hans Carl Hasselbalch
Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.
Clinical and laboratory haematology 2004;26(5):335-40.
2004: Per Boye Hansen; Hans Carl Hasselbalch
[Rituximab. A monoclonal CD20 antibody--hematological indications and possible treatments for immunoinflammatory diseases].
Ugeskrift for laeger 2004;166(6):466-9.
2003: Hans Carl Hasselbalch; Ole Weiss Bjerrum; Bjarne Anker Jensen; Nielsaage Tøffner Clausen; Per Boye Hansen; Henrik Birgens; Marianne Hamilton Therkildsen; Elisabeth Ralfkiaer
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
American journal of hematology 2003;74(4):238-42.
2003: Majken K Jensen; Mads N Holten-Andersen; Rikke Riisbro; Peter de Nully Brown; Maj Britt Larsen; Lars Kjeldsen; Lene Heickendorff; Nils Brünner; Hans Carl Hasselbalch
Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders.
European journal of haematology 2003;71(5):377-84.
2003: Majken K Jensen; Rikke Riisbro; Mads N Holten-Andersen; Peter de Nully Brown; Peter Junker; Nils Brünner; Hans Carl Hasselbalch
Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism.
European journal of haematology 2003;71(4):276-82.
2003: Iben Nielsen; Hans Carl Hasselbalch
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
American journal of hematology 2003;74(1):26-31.
2003: Hans Carl Hasselbalch
B-cell depletion with rituximab-a targeted therapy for Graves' disease and autoimmune thyroiditis.
Immunology letters 2003;88(1):85-6.
2003: Mathilde Skaarup Larsen; Hans Carl Hasselbalch
[Immunosuppressive treatment of the myelodysplastic syndrome].
Ugeskrift for laeger 2003;165(26):2654-7.
2002: Majken K Jensen; Rikke Riisbro; Peter de Nully Brown; Nils Brünner; Hans Carl Hasselbalch
Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.
European journal of haematology 2002;69(1):43-9.
2002: Hans Carl Hasselbalch; Nielsaage Tøffner Clausen; Bjarne Anker Jensen
Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin.
American journal of hematology 2002;70(2):92-9.
2002: Hans Carl Hasselbalch
[STI571 (Glivec)--a new drug for the treatment of chronic myeloid leukemia].
Ugeskrift for laeger 2002;164(22):2914-7.
2002: Majken K Jensen; Peter de Nully Brown; Sixtus Thorsen; Hans Carl Hasselbalch
Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders.
American journal of hematology 2002;69(3):185-91.
2002: Hans Carl Hasselbalch; Birgitte Ravn Juhl; Per Boye Hansen
[The myelodysplastic syndrome II. New therapeutic principles, course and prognosis].
Ugeskrift for laeger 2002;164(4):479-82.
2002: Hans Carl Hasselbalch; Birgitte Ravn Juhl; Per Boye Hansen
[The myelodysplastic syndrome I. Pathogenesis, clinical symptoms, diagnosis and differential diagnosis].
Ugeskrift for laeger 2002;164(4):476-9.
2001: Mikkel Faurschou; Hans Carl Hasselbalch; Ove Juul Nielsen
Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia.
European journal of haematology 2001;66(6):408-11.
2001: Hans Carl Hasselbalch; Hans Torben Mourits-Andersen; Bjarne Anker Jensen; Majken K Jensen; Ove Juul Nielsen
[Acute thrombotic complication at the debute of the Philadelphia chromosome-negative myeloproliferative syndrome].
Ugeskrift for laeger 2001;163(18):2478-81.
2001: Hans Carl Hasselbalch; Hans Torben Mourits-Andersen; Bjarne Anker Jensen; Majken K Jensen; Ove Juul Nielsen
[The chronic Philadelphia chromosome-negative myeloproliferative syndrome II. Clinical findings, diagnostics and treatment].
Ugeskrift for laeger 2001;163(18):2474-7.
2001: Hans Carl Hasselbalch; Hans Torben Mourits-Andersen; Bjarne Anker Jensen; Majken K Jensen; Ove Juul Nielsen
[The chronic Philadelphia chromosome-negative myeloproliferative syndrome I. Pathogenesis and pathophysiology].
Ugeskrift for laeger 2001;163(18):2471-3.
2001: Majken K Jensen; Peter de Nully Brown; B V Lund; Ove Juul Nielsen; Hans Carl Hasselbalch
Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count.
European journal of haematology 2001;66(3):143-51.
2000: Mikkel Faurschou; Ove Juul Nielsen; Majken K Jensen; Hans Carl Hasselbalch
High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders.
American journal of hematology 2000;65(2):136-40.
2000: Majken K Jensen; Peter de Nully Brown; Ove Juul Nielsen; Hans Carl Hasselbalch
Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area.
European journal of haematology 2000;65(2):132-9.
2000: Majken K Jensen; Peter de Nully Brown; B V Lund; Ove Juul Nielsen; Hans Carl Hasselbalch
Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders.
British journal of haematology 2000;110(1):116-24.
1999: Mikkel Faurschou; Ove Juul Nielsen; Per Boye Hansen; Birgitte Ravn Juhl; Hans Carl Hasselbalch
Fatal virus-associated hemophagocytic syndrome associated with coexistent chronic active hepatitis B and acute hepatitis C virus infection.
American journal of hematology 1999;61(2):135-8.
1999: JJ Michiels; Jack Kutti; P Stark; M Bazzan; Luigi Gugliotta; Roberto Marchioli; Martin Griesshammer; Perry van Genderen; Josette Brière; Jean-Jacques Kiladjian; Tiziano Barbui; Guido Finazzi; N I Berlin; T C Pearson; A C Green; S M Fruchtmann; Richard T Silver; E Hansmann; A Wehmeier; Eva Lengfelder; Raffaele Landolfi; Hans Michael Kvasnicka; Hans Carl Hasselbalch; Francisco Cervantes; J Thiele
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
The Netherlands journal of medicine 1999;54(2):46-62.
1998: Mikkel Faurschou; Ove Juul Nielsen; Per Boye Hansen; Hans Carl Hasselbalch
[Virus-associated hemophagocytic syndrome. Diagnosis and treatment].
Ugeskrift for laeger 1998;160(43):6198-200.
1997: Christian T Bonde; E Jakobsen; Hans Carl Hasselbalch
["Blue rubber bleb nevus syndrome"--or Bean's syndrome].
Ugeskrift for laeger 1997;159(27):4274-5.
1996: Hans Carl Hasselbalch; H T Mourits-Andersen; B A Jensen; Ove Juul Nielsen
[Anagrelide. A selective inhibitor of thrombopoiesis].
Ugeskrift for laeger 1996;158(12):1693-5.
1995: Hans Carl Hasselbalch; D Hovgaard; NI Nissen; P Junker
Serum hyaluronan is increased in malignant lymphoma.
American journal of hematology 1995;50(4):231-3.
1993: T Møller; Hans Carl Hasselbalch
[Hematological changes associated with human immunodeficiency virus (HIV-1) infection].
Ugeskrift for laeger 1993;155(19):1442-6.
1993: Hans Carl Hasselbalch
[Toxic shock syndrome in group A streptococcal infection].
Ugeskrift for laeger 1993;155(2):74-8.